Sociedad Americana de Hirudoterapia

Recurrent Trigger Finger (Post-Injection Failure)

Investigational use for trigger finger recurrent after corticosteroid injection failure; pre-surgical alternative explored in case series.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?
Not FDA-cleared for trigger finger. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for recurrent trigger finger is investigational.
¿Qué evidencia existe?
Tier C (investigational). Only case-series-level evidence; there are no randomized controlled trials. Evidence-based therapy for recurrent trigger finger after corticosteroid injection failure: repeat corticosteroid injection (limited to 2-3 total), percutaneous A1 pulley release, or open surgical release (high success rate >90 percent, ASSH-endorsed). Diabetes increases recurrence and decreases injection response.
Riesgos principales
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the palm and finger for 5 to 14 days
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Worsening of triggering after the procedure (transient)
  • Risk if a leech is placed too close to digital nerves or flexor tendon sheath
  • Permanent small scars at bite sites on the palm
  • Delay of definitive A1 pulley release surgery which has >90 percent success
Quién no debería considerar esto
  • Patients with finger contracture or fixed locked-in flexion (surgical release needed)
  • Patients within 4 weeks of corticosteroid injection at the site
  • Patients with active flexor tendon sheath infection (surgical emergency)
  • Patients with diabetic neuropathy of the hand
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not been offered A1 pulley release surgery
Qué preguntar a su clínico
  • Have I been offered A1 pulley release surgery (>90 percent success)?
  • Have I had repeat corticosteroid injection (up to 2-3 total)?
  • If I have diabetes, is my glycemic control optimized?
  • What evidence specifically supports leech therapy for trigger finger?
  • What is the practitioner's experience with leech placement on the palm?
  • Are leeches from an FDA-registered supplier and used only once?
  • What is the cost and is it covered by insurance? (typically not covered)
Cuándo buscar atención urgente
  • Sudden inability to flex or extend the finger (possible tendon rupture)
  • Severe palm pain with fever (rule out flexor tendon sheath infection — surgical emergency)
  • Spreading redness, warmth, pus, or red streaks (cellulitis or pyogenic flexor tenosynovitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

Qué NO significa esto

  • This is NOT FDA-cleared for trigger finger.
  • Case-series evidence does NOT establish efficacy versus A1 pulley release surgery (>90 percent success) or repeat corticosteroid injection.
  • It does NOT cure trigger finger — recurrence is high without definitive treatment.
  • It does NOT substitute for surgical release in fixed locked-in flexion.
  • It does NOT address diabetes, which is the strongest recurrence risk factor.

Clinical Profile

Category
musculoskeletal
ICD-10
M65.30, M65.311, M65.312, M65.321, M65.322
Safety tier
low

Evidence Summary

A substantial minority of trigger fingers recur after a first corticosteroid injection. No controlled clinical trial or case series of leech therapy for trigger finger has been published; use is investigational and mechanistic only, with a hypothesized anti-inflammatory effect on flexor tenosynovial swelling. Standard alternatives include a second corticosteroid injection, percutaneous release, or open A1 pulley release. This entry addresses recurrent (post-injection) presentations and is distinct from the primary first-presentation trigger-finger entry.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Bhatia A et al. (2021), n=14

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active local infection
  • Recent (<4 weeks) local corticosteroid injection
  • Locked finger requiring acute surgical release

Related Conditions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Recurrent Trigger Finger (Post-Injection Failure) — Hirudotherapy Evidence | ASH